MedTrace Logo

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

NCT00749333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2009-04-30

No results posted yet for this study

Summary

The purpose of this study is to determine how well tolerated and safe AZD8566 is at different dose levels. This study will also determine how AZD8566 is distributed around the body and how it leaves the body.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD8566

solution. Specific dose will be selected by the safety review committee

DRUG

Placebo

Single 10ml oral solution.

Sponsors & Collaborators

Principal Investigators

  • William Fahy, MD,MA, MBBS (Hons) · Clinical Pharmacology Unit, Queen's Medical Centre, Nottingham, NG7 2UH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749333 on ClinicalTrials.gov